Searchable abstracts of presentations at key conferences in endocrinology

ea0021p88 | Clinical practice/governance and case reports | SFEBES2009

Phaeochromocytoma/paraganglionoma patients in a joint endocrine genetic clinic setting

Stewart Sue , Ayuk John , Campbell Chris , Cole Trevor

A 19-year-old student was referred with a history of increasing anxiety attacks, palpitations and breathlessness. Blood pressure and urinary catecholamine levels were elevated. MRI imaging confirmed a para-aortic paraganglionoma and MIBG scan highlighted bony metastases. The patient underwent surgery for the primary lesion and targeted MIBG therapy for metastases.Age of onset, malignant disease and metastases increase the likelihood of a genetic cause an...

ea0021p180 | Diabetes and metabolism | SFEBES2009

Impact of glucocorticoids upon lipogenesis and β-oxidation in skeletal muscle

Morgan Stuart , Gathercole Laura , Stewart Paul , Smith Dave , Tomlinson Jeremy

Glucocorticoid excess is characterized by increased adiposity, skeletal myopathy and insulin resistance. Although there is a strong inverse correlation between intramuscular triglyceride (IMTG) levels and insulin sensitivity, the impact of glucocorticoids upon the processes that regulate skeletal muscle lipid metabolism has not been explored.Mouse C2C12 skeletal myocytes were grown to confluence and differentiated into myotubes in chemically defined medi...

ea0021p349 | Steroids | SFEBES2009

Urinary steroid metabolite profiling in 11β-HSD1 and H6PDH transgenic mice

Semjonous Nina , Hughes Beverly , Walker Elizabeth , Lavery Gareth , Stewart Paul

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inactive glucocorticoid to their active form (cortisone to cortisol in humans, 11-dehydrocorticosterone (11-DHC) to corticosterone in mice), and is dependent upon the presence of cofactor NADPH generated by the enzyme hexose-6-phosphate (H6PDH) for its activity. The 11β-HSD1/H6PDH system is implicated in the pathogenesis of the metabolic syndrome by generating tissue specific glucocorticoid excess. The ...

ea0021p357 | Steroids | SFEBES2009

6-Phosphogluconate dehydrogenase: an NADPH-generating enzyme in the lumen of the endoplasmic reticulum

Bujalska Iwona , Ride Jonathan , Stewart Paul , Walker Elizabeth

6-Phosphogluconate dehydrogenase (6PGDH) is the third enzyme of the oxidative phase of the pentose phosphate pathway. The cytosolic form of this pathway is well characterised, but the details and significance of the endoplasmic reticulum (ER) version are only beginning to be understood. We have previously identified hexose-6-phosphate dehydrogenase (H6PDH), which catalyses the first two steps of this pathway within the lumen of the ER, as a pivotal regulator of ER reductases s...

ea0021p363 | Steroids | SFEBES2009

Is increased 11β-HSD1 expression a key factor underpinning intrinsic and extrinsic skin aging?

Tiganescu Ana , Mayes Andrew , Hardy Rowan , Stewart Paul , Walker Elizabeth

Glucocorticoids are highly detrimental to skin integrity and function both when used locally for anti-inflammatory treatments and during conditions of raised systemic concentrations such as Cushing’s syndrome. Many of the adverse effects of glucocorticoids on skin are also symptoms associated with natural intrinsic aging and extrinsic photoaging.Locally, glucocorticoid availability is regulated independently of circulating levels by 11β-hydroxy...

ea0019oc12 | Neuroendocrine and Steroids | SFEBES2009

Absence of hexose-6-phosphate dehydrogenase specifically induces skeletal myopathy in mice

Semjonous N , Lavery G , Walker E , Stewart P

Murine 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) catalyses the conversion of inactive 11-dehydrocorticosterone (A) to active corticosterone (B) and plays a key role in metabolic homeostasis. The directionality of this enzyme is dependent upon the presence of NADPH, a cofactor produced by hexose-6-phosphate dehydrogenase (H6PDH). In accord with this, H6PDH KO mice have no reductase and increased dehydrogenase activity of 11βHSD1. Interestingly, H6PDH KO m...

ea0019oc19 | Cardiovascular metabolism | SFEBES2009

Glucocorticoid and insulin regulation of lipogenesis in human adipose tissue

Gathercole L , Buljalska I , Stewart P , Tomlinson J

Patients with glucocorticoid (GC) excess, Cushing’s syndrome, develop a classical phenotype characterized by insulin resistance and central obesity. Whilst it is clear that GCs are essential for adipocyte differentiation, their impact upon many of the processes that regulate lipid accumulation has not been explored in detail. De novo lipogenesis involves carboxylation of acetyl CoA to malonyl-CoA by acetyl CoA carboxylase (ACC), which is subsequently converted to p...

ea0019p133 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Adrenal hypertrophy occurs in concert with insulin resistance following high fat feeding of two different strains of rat

McNeilly A , Williamson R , Balfour D , Sutherland C , Stewart C

The incidence of type 2 diabetes (T2DM) has doubled over the past decade. Obesity induced insulin resistance is associated with T2DM and the metabolic syndrome (including hypertension, and dyslipidemia). Diets high in saturated fat are largely to blame for the current obesity epidemic. High-fat feeding of animals increases circulating corticosterone levels, in addition to changes in glucose homeostasis. The relationship between insulin sensitivity and abnormal hypothalamic&#15...

ea0019p135 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Knockdown of H6PDH in C2C12 muscle cells impairs 11β-HSD1 activity and myogenic differentiation

Saqib KM , Sherlock M , Walker EA , Stewart PM , Lavery GG

NADPH generated by hexose-6-phosphate dehydrogenase (H6PDH) within the lumen of the endoplasmic reticulum (ER) drives the reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-βHSD1) allowing the production of active glucocorticoids. H6PDH knockout (H6PDHKO) mice develop a vacuolating myopathy, reduced muscle mass and display activation of the ER stress response. However, the role of glucocorticoids and 11β-HSD1 in the myopathy phenotype is not clear...

ea0019p189 | Endocrine tumours and neoplasia | SFEBES2009

Genetics in mainstream medicine: best practice review

Stewart S , Watkinson J , Franklyn J , Woodward E , Cole T

Medullary thyroid cancer (MTC) is rare and mainly sporadic. About ≤25% of cases are inherited from a Ret protooncogene (RET) mutation. >90% of positive mutations develop MTC, either as familial (FMTC), or as part of MEN2. Early detection and treatment of MTC with total thyroidectomy improves prognosis.In 2006, as part of a project to deliver genetics into mainstream medicine, a multidisciplinary clinic (MDC) comprising a specialist thyroid surg...